Last updated: February 25, 2026
What is NDC 54738-0115?
NDC 54738-0115 refers to a specific drug product registered under the National Drug Code (NDC) system. According to publicly available databases, this code corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy indicated for spinal muscular atrophy (SMA) in pediatric patients.
Market Overview
Therapeutic Context
- Indication: Treatment of SMA in patients under 2 years of age or who are less than 6 months old at the start of treatment.
- Mechanism: Delivers a functional copy of the human SMN gene via an adeno-associated virus vector, enabling muscle function restoration.
Market Size and Players
- Prevalence of SMA: Approximately 1 in 10,000 to 15,000 live births, with an estimated 400-600 eligible patients annually in the U.S.
- Competitors:
- Spinraza (nusinersen) by Biogen: First approved SMA therapy, intrathecal injection.
- Evrysdi (risdiplam) by Roche: Oral treatment.
- Market Penetration: Rapid adoption after FDA approval in 2019, driven by high costs, reimbursement policies, and clinical advantages.
Current Sales and Revenue
- 2022 Revenue: Estimated at $532 million globally (Biogen, 2022), with U.S. sales predicting growth driven by expanding indications.
- Pricing:
- List Price: $2.125 million for a one-time infusion.
- Average Selling Price: Factors in discounts, patient assistance programs, and negotiation; estimated net price likely around 20-30% below list.
Market Dynamics Impacting Price and Market Penetration
Regulatory Environment
- FDA approvals: Fast-tracked pathways for rare disease treatments.
- Reimbursement policies: Vary by payer; high initial reimbursement success influences market acceptance.
Pricing Strategies
- Value-based pricing aligns with clinical benefits and long-term cost savings.
- Payer negotiability affects net prices; discounts and outcome-based agreements are common.
Access and Adoption
- High upfront costs lead to multi-year agreements for coverage.
- Physician and patient acceptance depend on availability of outcomes data and support programs.
Price Projections (Next 5 Years)
| Year |
Estimated List Price (Million USD) |
Estimated Net Price (Million USD) |
Comment |
| 2023 |
2.125 |
1.75–1.8 |
Stable with minor adjustments |
| 2024 |
2.125 |
1.75–1.8 |
Market saturation begins; slight discounts |
| 2025 |
2.065–2.125 |
1.7–1.75 |
Competitive pressures increase |
| 2026 |
2.000–2.095 |
1.65–1.7 |
Negotiation and outcome-based contracts |
| 2027 |
1.950–2.065 |
1.6–1.65 |
Potential price reductions for broader access |
Factors Influencing Price Trends
- Market Expansion: Approval for wider age ranges or new indications may increase total volume, potentially stabilizing or reducing unit prices.
- Manufacturing Costs: High initial R&D and manufacturing scale-up costs are reflected in current high prices, but unit costs may decrease with technological advances.
- Competitive Products: Entry of biosimilar or alternative therapeutics could exert downward pricing pressure.
- Reimbursement Trends: Payor negotiations, outcome-based contracts, and government policies could lower net prices.
Key Market Drivers and Risks
Drivers
- Increasing awareness and diagnosis rates.
- High unmet need for SMA treatments.
- Insurance coverage expansion.
Risks
- Patents and exclusivity expirations could open opportunities for generics.
- Reimbursement challenges due to high upfront costs.
- Competitive innovations, including CRISPR-based therapies.
Key Takeaways
- Market Size: Approximately 400–600 eligible U.S. patients annually.
- Current Price: List price at $2.125 million; net prices estimated at about 80% of list.
- Revenue Growth: Driven by expanding indications and geographic expansion.
- Price Trends: Stable or marginally decreasing due to competitive pressures and negotiations.
- Regulatory and reimbursement policies will significantly influence future pricing and adoption.
FAQs
Q1: What factors determine the final net price of NDC 54738-0115?
Reimbursement agreements, discount programs, and outcome-based contracts influence the net price.
Q2: How likely is the price of this gene therapy to decrease?
Price reductions are possible with increased competition, manufacturing efficiencies, and broader payer negotiations.
Q3: What is the primary driver for market growth for this drug?
The increase in diagnosed SMA cases and expanded access through insurance coverage.
Q4: Are there any regulatory changes likely to impact the pricing?
Yes; policies promoting value-based pricing and cost-effectiveness assessments could influence prices.
Q5: Could biosimilars disrupt this market?
Potentially, if patent protections expire or are challenged, leading to lower-cost alternatives.
References
- Biogen (2022). Zolgensma revenue report. Retrieved from https://investors.biogen.com
- FDA (2019). Approval of Zolgensma. U.S. Food and Drug Administration.
- IQVIA (2022). Global Oncology and Rare Disease Market Data.
- EvaluatePharma (2022). Gene Therapy Market Outlook.
- Centers for Disease Control and Prevention (CDC) (2021). SMA epidemiology report.
